Page breadcrumb nav

VAERS Report 2157285

Case Report Section

Détails du rapport Vaer

Âge: 34 ans

Genre: Male

Région : Outside US

Patient décédé?
Non
Renseignements sur les vaccins

Nom: COVID19 (COVID19 (MODERNA))

Type : Coronavirus 2019 vaccine

Fabricant: MODERNA

Lot: 000060asc04/0


Date de réception du rapport
2022-03-04
Date à laquelle le formulaire est complèté
Date de vaccination
2022-02-06
Date d’apparition
1
Nombre de jours (date d’apparition – date de vaccination)
1
Description de l’événement indésirable

hyperpyrexia throughout the day following vaccination, erythema at the injection site; hyperpyrexia throughout the day following vaccination, erythema at the injection site; this case was received (reference number: it-minisal02-842159) on 28-feb-2022 and was forwarded to moderna on 28-feb-2022. this regulatory authority case was reported by a physician and describes the occurrence of hyperpyrexia (hyperpyrexia throughout the day following vaccination, erythema at the injection site) and injection site joint erythema (hyperpyrexia throughout the day following vaccination, erythema at the injection site) in a 34-year-old male patient who received mrna-1273 (spikevax) (batch no. 000060a sc 04/05/22) for covid-19 vaccination. no medical history information was reported. on 06-feb-2022, the patient received dose of mrna-1273 (spikevax) (intramuscular) .25 milliliter. on 07-feb-2022, the patient experienced hyperpyrexia (hyperpyrexia throughout the day following vaccination, erythema at the injection site) (seriousness criterion medically significant) and injection site joint erythema (hyperpyrexia throughout the day following vaccination, erythema at the injection site) (seriousness criterion medically significant). at the time of the report, hyperpyrexia (hyperpyrexia throughout the day following vaccination, erythema at the injection site) and injection site joint erythema (hyperpyrexia throughout the day following vaccination, erythema at the injection site) was resolving. the action taken with mrna-1273 (spikevax) (intramuscular) was unknown. for mrna-1273 (spikevax) (intramuscular), the reporter did not provide any causality assessments. no concomitant medications were provided. no treatment medications were reported. company comment: this is a regulatory authority case concerning a 34-year-old, male patient with no reported medical history, who experienced the unexpected serious (medically significant according to regulatory authority) events of hyperpyrexia and injection site erythema. the events occurred approximately 1 day after the unknown dose number of mrna-1273 vaccine administration. no reported treatment information. the outcome of the events were resolving from the time of last observation. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report.; reporter's comments: the severity is changed from 'non-serious' to 'severe' as' hyperpyrexia 'occurs, an event present in the ime list.; sender's comments: this is a regulatory authority case concerning a 34-year-old, male patient with no reported medical history, who experienced the unexpected serious (medically significant according to regulatory authority) events of hyperpyrexia and injection site erythema. the events occurred approximately 1 day after the unknown dose number of mrna-1273 vaccine administration. no reported treatment information. the outcome of the events were resolving from the time of last observation. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report

Données de laboratoire
na
Liste des symptômes
injection site joint erythema hyperpyrexia
Patient décédé?
Non
Date de décès
N/A
Anomalie congénitale
false
Vaccin administré par :
Unknown
Vaccin acheté par :
Inconnu
Visite d’un patient à l’urgence?
Non
Patient hospitalisé?
Non
Séjour à l’hôpital
Non
Nombre de jours à l’hôpital
Non spécifié
Invalidité permanente?
Non
Allergies:
na
Maladie actuelle
na